Navigating CML Treatment: A Patient-Centered Approach - Episode 7
ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment
Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.
Video Player is loading.
Video content above is prompted by the following:
- Can you tell us about the trial design, key end points, and your impressions of the data?
- With the recent FDA approval of asciminib in the first-line (1L) setting, how will you incorporate this into your practice?
- Are there particular patients whom you would consider for asciminib vs first- or second-generation tyrosine kinase inhibitors?
- Please share any anticipated similarities or differences in your clinical practice now that asciminib has received FDA approval in the 1L setting.
Related Content:
